tecarfarin

Tecarfarin is a novel, oral, reversible vitamin K antagonist (VKA) anticoagulant under late-stage development for the prevention of thrombosis and thromboembolism. It is designed to provide safer and more effective chronic anticoagulation than warfarin, particularly in patients with rare cardiovascular conditions such as those with implanted mechanical circulatory support devices (e.g., LVADs) or end-stage kidney disease plus atrial fibrillation. Unlike warfarin, which is metabolized by the cytochrome P450 pathway and subject to significant drug-drug interactions and genetic variability, tecarfarin is metabolized primarily via human carboxyl esterase 2 (CES2), reducing interaction risks. Tecarfarin has received FDA orphan drug designation for use in patients with mechanical heart support devices and fast-track status for end-stage kidney disease with atrial fibrillation. Clinical trials have shown it to be well-tolerated, with efficacy comparable to warfarin but potentially fewer adverse events related to bleeding or clotting[1][2][4][5][6][7][8].

Other names

ATI-5923ATI5923ATI 5923tecarfarin